Myoviridae T4D.
Another bacteriophage strain in the PreforPro blend, targeting specific harmful bacteria in your gut. Selectively destroys targeted harmful bacteria in your gut using the most well-understood phage mechanism in science.
Reviewed March 2026
- Category
- General
- Also filed under
- Targets specific harmful gut bacteriaRelated to well studied T4 phage familyPart of studied PreforPro blend
What Myoviridae T4D is, and what it does.
- Does it work
- Suits people building a gut routine around probiotics and fibre who want the coliform side addressed too. It only comes as part of the four-phage blend.
- How much to take
- 15 mg as part of the PreforPro blend. T4D doesn't have standalone dosing because it's always delivered as part of the 4-phage cocktail.
- Time to feel it
- No same-day effect. Where the four-phage blend has been measured, changes in gut bacterial composition and comfort showed up across roughly four weeks.
- The first dose
- No perceptible effects. T4D phages begin infecting target bacteria within minutes of reaching the gut, but the scale is microscopic.
- With regular use
- Weeks 3-4: gradual improvements in digestive comfort as the bacterial balance shifts. Effects are subtle, not dramatic.
- How well tolerated
- Well tolerated. T4 phages have been studied for 80+ years. They can only infect specific bacteria. Zero ability to harm human cells.
- How it feels
- Invisible in the best way. You don't feel the phages. You notice the result: fewer random GI issues over time.
- The overlooked benefit
- T4 binds lipopolysaccharide and OmpC on the outer membrane of coliforms. Gram-positive probiotic species have no outer membrane, so they're not targets at all.
15mg a day is where Myoviridae T4D works.
Source: Gindin et al., 2019 (PreforPro blend study)
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Kills harmful gut bacteria selectively
- Enhances probiotic effectiveness
Questions people ask about Myoviridae T4D.
- Why is T4 so well-studied?
- Right place, right time. When scientists in the 1940s needed a simple model to understand genetics, T4 was easy to grow and study. It became the E. coli of viruses.
- If T4 targets E. coli, will it kill my good E. coli?
- T4D targets specific E. coli strains. Not all E. coli are the same. The phage is selective even within E. coli species, hitting harmful variants while leaving beneficial ones.
- Can I just take T4 phage alone for gut health?
- You could, but it wouldn't cover enough ground. Gut health problems involve many bacterial species. That's why PreforPro uses four different phages.
- How do phages avoid killing good bacteria?
- Lock and key. Each phage has proteins on its tail that only fit receptors on specific bacteria. If the key doesn't fit, the phage bounces off harmlessly.
- Do antibiotics kill phages?
- No. Antibiotics target bacteria, not viruses. Phages are viruses. However, if antibiotics kill the phage's target bacteria, the phages lose their food source and decline naturally.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Myoviridae T4D is one of the lytic coliphage strains that make up the PreforPro preparation. The two describe the same class of material, so a formula listing both is describing one prebiotic phage input rather than two.
Lytic coliphages break open target Escherichia coli cells and release their carbon and nitrogen into the colonic lumen, which the surviving culture can take up. This is why phage preparations are formulated alongside live cultures rather than on their own.
T4-type phages attach to receptors found on coliform outer membranes and cannot adsorb to Gram-positive lactobacilli, so the culture passes through unaffected while competing coliforms are reduced. That selectivity is the reason the pair is used together.
Coliphages have no receptor on bifidobacteria, so the phage narrows the coliform population without acting on the bifidobacteria in the same capsule. Nutrients released by lysis are available to the resident bifidobacteria.
T4-type Myoviridae adsorb to lipopolysaccharide and outer membrane receptors specific to Escherichia coli, structures that Gram-positive lactobacilli do not carry. That host restriction is why a coliphage preparation can be co-formulated with a lactobacillus without lysing it. The specificity is established phage biology. Whether removing coliforms benefits the lactobacillus population is a separate and much weaker claim.
Bacteriophages infect bacteria only, so a probiotic yeast is untouched by a coliphage preparation and the two can share a capsule. Saccharomyces boulardii is also acid tolerant and does not need the enteric protection a phage preparation may need. The compatibility is mechanical rather than a demonstrated combined effect.
Bifidobacteria lack the outer membrane receptors that T4-type phages recognise, so they are not lysed by a coliphage preparation. That makes them a routine co-ingredient in phage-containing blends. Co-formulation compatibility is the established part. An additive effect on colonisation is not.
Inulin is fermented by bifidobacteria and other saccharolytic residents into short-chain fatty acids, a well-characterised prebiotic effect. A phage preparation works on a different axis, reducing a specific bacterial host rather than feeding anything. Blends pair them because the mechanisms do not overlap, not because a combination has been measured.
Galactooligosaccharides resist digestion in the small intestine and are fermented in the colon, shifting the community toward bifidobacteria. Pairing that with a host-specific phage is a two-lever approach, feeding one group while reducing another. The pairing itself has not been measured in the sources available here.
Resistant starch escapes small intestinal digestion and is fermented in the colon, with butyrate as a major product. It occupies a different niche from a phage preparation, which does not supply energy to anything. Read the combination as complementary in design rather than clinically demonstrated.
Butyrate is the preferred energy substrate of colonocytes and is normally produced by fermentation of resistant carbohydrate. Supplying it directly bypasses the fermentation step, while a phage preparation acts on the bacterial population itself. The two do not interfere with each other.
Partially hydrolysed guar gum ferments more slowly along the colon than inulin, producing less rapid gas formation. It is a common choice in blends aimed at people who tolerate inulin poorly. The pairing with a phage preparation is a formulation decision.
Glutamine is the principal respiratory fuel for small intestinal enterocytes and a nitrogen donor for nucleotide synthesis in rapidly dividing mucosal cells. It is a common gut-formula companion to microbial ingredients because it acts on the host tissue rather than the microbes. The metabolic role is established. A combined effect is not something the available sources measure.
Zinc carnosine is a coordination complex that dissolves slowly and releases zinc along the mucosal surface, which is why it appears in gut formulas. It has no interaction with phage particles. The pairing is complementary by design, and the mucosal work rests on its own separate literature.
Activated charcoal adsorbs a wide range of organic molecules and particulates in the lumen, and a protein-coated virus particle is exactly the kind of material it can bind. Taking the two at the same time is likely to reduce the number of viable phage reaching their target. Separating the doses is the sensible formulation answer, and this is a mechanistic expectation rather than a measured interaction.
Bentonite carries a high negatively charged surface area that binds proteins and viral particles in suspension, a property used deliberately in water treatment. Co-administration with a phage preparation would be expected to reduce the delivered dose. This is mechanistic reasoning from the material's known behaviour.
A bacteriophage capsid is protein, and supplemental proteases are active in the upper gastrointestinal tract where a phage preparation is still transiting. High protease loads taken in the same dose are a plausible route to reduced viable particle counts. Formulators usually separate the two or use delayed release for this reason.
Betaine hydrochloride is taken to raise gastric acidity, and phage particles vary widely in their tolerance of low pH. A preparation that is not acid-protected may lose viable count faster in a more acidic stomach. This is a mechanistic caution drawn from phage stability behaviour, not a measured clinical interaction.
Talk to a doctor before taking Myoviridae T4D if any of these apply to you: Individual strain effects unknown, Bacteriophage supplementation is still emerging. These are flags to check first, not effects Myoviridae T4D is known to cause.
Not medical advice. Show the label to your pharmacist.What Myoviridae T4D actually does.
Bacteriophages are viruses that replicate only inside bacterial cells. They carry no machinery for getting into or copying themselves in human cells, and they sit inert next to your own tissue.
T4-type Myoviridae recognise their host through specific receptors on the Escherichia coli surface, mainly lipopolysaccharide and the outer membrane protein OmpC. That's why their host range is narrow.
A lytic phage finishes its cycle by sticking to the host, injecting its genome, turning the cell's synthesis over to making new particles, and popping the cell open with endolysin and holin proteins.
Gram-positive residents such as lactobacilli and bifidobacteria don't have the outer membrane structures a coliphage grabs, so a coliphage preparation leaves them alone.
Where Myoviridae T4D comes from.
A phage is a virus that only infects bacteria. To make one, producers grow the target bacteria on purpose, add the phage, and let it multiply until the bacteria burst. Everything from the bacteria is then filtered out, which is the hardest part of the process. What is left is counted, freeze-dried with a sugar to help it survive drying, and put into a capsule that usually protects it from stomach acid.
Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.
A characterised Escherichia coli host strain is grown in a defined broth to the density needed for infection. The host strain is the production substrate, not an ingredient in the finished product.
The phage seed stock is added at a set multiplicity of infection and the culture is held until lysis clears it. Yield is expressed in plaque-forming units per millilitre of lysate.
The lysate is centrifuged and passed through successive filtration stages, commonly tangential flow filtration, to remove cell debris, host protein and endotoxin. Endotoxin removal is the step that governs how much downstream processing is needed, since the host is a Gram-negative organism.
Viable particles are counted by plaque assay and the concentrate is blended with a carrier to a declared plaque-forming unit count per serving. The declared number is a viability count at time of manufacture, so overage and storage conditions matter.
The preparation is freeze-dried with a cryoprotectant such as a sugar or a polyol to hold viability through drying, then encapsulated, often with delayed-release or acid-protective packaging.
Getting Myoviridae T4D from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The essence, in one line each.
- In a 4-week randomised, double-blind, placebo-controlled trial in 68 healthy adults, adding a bacteriophage blend containing T4D to a Bifidobacterium animalis subsp. lactis probiotic showed a within-group improvement in a self-reported gut symptom score (p = 0.01) and a larger rise in Lactobacillus and short-chain fatty acid producing bacteria than the probiotic alone.Randomised trial. Grubb et al., 2020 (Nutrients). PMID 32824480 ↗
These are the studies our verdict leans on, chosen from the 8 we read for Myoviridae T4D. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
